{
    "brief_title": "Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)",
    "phase": "Phase 2",
    "drugs": "['Vinorelbine', 'Capecitabine', 'Trastuzumab']",
    "drugs_list": [
        "Vinorelbine",
        "Capecitabine",
        "Trastuzumab"
    ],
    "diseases": "['Breast Cancer']",
    "diseases_list": [
        "Breast Cancer"
    ],
    "enrollment": "178.0",
    "inclusion_criteria": "inclusion criteria: \n\n women aged 18-70 years old; \n\n T \u22641cm and negative lymph node confirmed by histopathology after early breast cancer surgery \n\n HER2 positive confirmed by histopathology after early breast cancer surgery\uff08HER2-positive breast cancer defined as a positive in situ hybridization test or an Immunohistochemistry (IHC) status of 3+. If IHC is 2+, a negative in situ hybridization (Fluorescence in situ hybridization (FISH), Chromogenic in situ hybridization (CISH) , or Silver in situ hybridization (SISH)) test is required by local laboratory testing.) \n\n Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; \n\n Has adequate organ function meeting the following criteria: (1) adequate bone marrow function: hemoglobin \u2265 90 g/L (no blood transfusion within 14 days); absolute neutrophil count \u2265 1.5 x 109 /L; platelet count \u2265 100 * 109 /L; (2)adequate liver and kidney function: Alanine Aminotransferase (ALT) \u2264 3\u00d7upper limit of normal (ULN), Aspartate Aminotransferase (AST) \u2264 3\u00d7ULN, Total Bilirubin (TBIL)\u2264 1.5\u00d7ULN, serum creatinine \u2264 1\u00d7ULN\uff0cand with endogenous creatinine clearance rate of >50 ml/min (Cockcroft-Gault formula). \n\n Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up. \n\n ",
    "exclusion_criteria": ": \n\n Has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy or endocrine therapy\uff09; \n\n Has bilateral breast cancer; \n\n Has previous history of additional malignancy, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ. \n\n Has metastic (Stage 4) breast cancer; \n\n Is pregnant, is breast feeding women, or women of childbearing age who cannot practice effective contraceptives; \n\n Patients participating in other clinical trials at the same time; \n\n Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left ventricular ejection fraction (LVEF) < 50% (cardiac ultrasound); severe cardio cerebral vascular disease within the 6 months previous of randomization (such as unstable angina, chronic heart failure, uncontrolled hypertension with blood pressure>150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control; patients with severe hypertension; \n\n Has severe or uncontrolled infection; \n\n Has a history of psychotropic substance abuse and were unable to abandon drug habits, or those with history of mental disorders; \n\n the researchers judged patients to be unsuitable for the study.",
    "brief_summary": "This is a prospective, open-lable Phase II clinical trial (ORCHID study) evaluating the effectiveness and safety of oral vinorelbine or capecitabine combined with trastuzumab as adjuvant treatment for patients with lymph node negative, HER-2 positive and small tumor size breast cancer",
    "NCT_ID": "NCT04296162"
}